Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Assess which option is safer for your needs—software or hardware wallets—by weighing security risks, accessibility, and practical safeguards.
21,982 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Looking for steady income in a volatile market? This guide highlights three high-yield energy stocks march investors ...
A big stake in Sotera Health has caught the market's eye as shares slide. This article breaks down what a $175 millio...
Two crypto stock heavyweights drop sharply as the Clarity Act targets passive stablecoin yields, threatening Circle’s...
As biotech earnings season unfolds, Precigen (PGEN) 2025 earnings take center stage. This guide breaks down what to m...
In a world of market swings, a simple, broad-based approach can anchor your portfolio. The Vanguard Total Stock Marke...
When margins rebound in the energy sector, even senior executives may trim holdings to align with evolving risk and o...
NWN’s Q1 2026 results reveal how the company balances growth with profitability. This analysis breaks down the number...
For decades, a handful of dividend stocks have quietly grown wealth through reliable payouts and strategic resilience...
Bank of America signals a noticeable pullback in card use across its customers, adding to a growing picture of cautio...
Axsome Therapeutics rode a powerful April rally driven by Auvelity performance and pipeline momentum. This article br...
Berkshire Hathaway stands at a pivotal crossroads as a new era begins. This article breaks down five-year scenarios, ...